MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Sakura Yamamura,Mohammed Eslam,Takumi Kawaguchi,Tsubasa Tsutsumi,Dan Nakano,Shinobu Yoshinaga,Hirokazu Takahashi,Keizo Anzai,Jacob George,Takuji Torimura +9 more
374
TL;DR: This work aimed to compare the diagnostic accuracy of the MAFLD definition vs the existing NAFLD criteria to identify patients with significant fibrosis and to characterize the impact of mild alcohol intake.
read more
Abstract: BACKGROUND & AIMS Diagnostic criteria for metabolic associated fatty liver disease (MAFLD) have been proposed, but not validated. We aimed to compare the diagnostic accuracy of the MAFLD definition vs the existing NAFLD criteria to identify patients with significant fibrosis and to characterize the impact of mild alcohol intake. METHODS We enrolled 765 Japanese patients with fatty liver (median age 54 years). MAFLD and NAFLD were diagnosed in 79.6% and 70.7% of patients respectively. Significant fibrosis was defined by FIB-4 index ≥1.3 and liver stiffness ≥6.6 kPa using shear wave elastography. Mild alcohol intake was defined as <20 g/day. Factors associated with significant fibrosis were analysed by logistic regression and decision-tree analyses. RESULTS Liver stiffness was higher in MAFLD compared to NAFLD (7.7 vs 6.8 kPa, P = .0010). In logistic regression, MAFLD (OR 4.401; 95% CI 2.144-10.629; P < .0001), alcohol intake (OR 1.761; 95% CI 1.081-2.853; P = .0234), and NAFLD (OR 1.721; 95%CI 1.009-2.951; P = .0463) were independently associated with significant fibrosis. By decision-tree analysis, MAFLD, but not NAFLD or alcohol consumption was the initial classifier for significant fibrosis. The sensitivity for detecting significant fibrosis was higher for MAFLD than NAFLD (93.9% vs 73.0%). In patients with MAFLD, even mild alcohol intake was associated with an increase in the prevalence of significant fibrosis (25.0% vs 15.5%; P = .0181). CONCLUSIONS The MAFLD definition better identifies a group with fatty liver and significant fibrosis evaluated by non-invasive tests. Moreover, in patients with MAFLD, even mild alcohol consumption is associated with worsening of hepatic fibrosis measures.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
Eduardo Vilar-Gomez,Eduardo Vilar-Gomez,Luis Calzadilla-Bertot,Vincent Wai-Sun Wong,Marlen Castellanos,Rocio Aller-de la Fuente,Mayada Metwally,Mohammed Eslam,Licet Gonzalez-Fabian,María Alvarez-Quiñones Sanz,Antonio Felix Conde-Martin,Bastiaan De Boer,Duncan McLeod,Anthony W.H. Chan,Naga Chalasani,Jacob George,Leon A. Adams,Manuel Romero-Gómez +17 more
- 01 Aug 2018
TL;DR: In this paper, the authors describe long-term outcomes and evaluate the effects of clinical and histologic parameters on disease progression in patients with advanced nonalcoholic fatty liver disease (NAFLD) with bridging fibrosis.
447
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.
TL;DR: In this article, the authors provided an overview of the current literature to support the notion that NAFLD is a multisystem disease and showed that there are probably multiple underlying mechanisms by which NASD might increase the risk of cardiovascular disease, type 2 diabetes, and extrahepatic complications.
402
Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
TL;DR: The change from NAFLD to MAFLD criteria may identify a greater number of individuals with metabolically complicated fatty liver and increased risk for CVD.
367
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement
Mohammed Eslam,Naim Alkhouri,Pietro Vajro,Ulrich Baumann,Ram Weiss,Piotr Socha,Claude Marcus,Way Seah Lee,Deirdre Kelly,Gilda Porta,Mohamed Abdel-Salam El-Guindi,Anna Alisi,Jake P. Mann,Nezha Mouane,Nezha Mouane,Louise A. Baur,Anil Dhawan,Jacob George +17 more
TL;DR: In this article, an international panel of experts proposed an overarching framework for paediatric fatty liver diseases and an age-appropriate MAFLD definition based on sex and age percentiles.
214
Global multi-stakeholder endorsement of the MAFLD definition
TL;DR: In this article , the authors endorse both the name metabolic (dysfunction)-associated fatty liver disease (MAFLD) as an overarching term and its definition for fatty liver diseases associated with metabolic dysregulation.
193
References
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
François Mach,Colin Baigent,Alberico L. Catapano,Konstantinos C. Koskinas,Manuela Casula,Lina Badimon,M. John Chapman,Guy De Backer,Victoria Delgado,Brian A. Ference,Ian D. Graham,Alison Halliday,Ulf Landmesser,Borislava Mihaylova,Terje R. Pedersen,Gabriele Riccardi,Dimitrios J. Richter,Marc S. Sabatine,Marja-Riitta Taskinen,Lale Tokgozoglu,Olov Wiklund,Christian Mueller,Heinz Drexel,Victor Aboyans,Alberto Corsini,Wolfram Doehner,Michel Farnier,Bruna Gigante,Meral Kayıkçıoğlu,Goran Krstacic,Ekaterini Lambrinou,Basil S. Lewis,Josep Masip,Philippe Moulin,Steffen E. Petersen,Anna Sonia Petronio,Massimo F Piepoli,Xavier Pintó,Lorenz Räber,Kausik K. Ray,Željko Reiner,Walter F Riesen,Marco Roffi,Jean-Paul Schmid,Evgeny Shlyakhto,Iain A. Simpson,Erik S.G. Stroes,Isabella Sudano,Alexandros D Tselepis,Margus Viigimaa,Cecile Vindis,Alexander Vonbank,Michal Vrablik,Mislav Vrsalovic,José Luis Zamorano,Jean-Philippe Collet,Stephan Windecker,Veronica Dean,Donna Fitzsimons,Chris P Gale,Diederick E. Grobbee,Sigrun Halvorsen,Gerhard Hindricks,Bernard Iung,Peter Jüni,Hugo A. Katus,Christophe Leclercq,Maddalena Lettino,Béla Merkely,Miguel Sousa-Uva,Rhian M. Touyz,Djamaleddine Nibouche,Parounak H. Zelveian,Peter Siostrzonek,Ruslan Najafov,Philippe van de Borne,Belma Pojskic,Arman Postadzhiyan,Lambros Kypris,Jindřich Špinar,Mogens Lytken Larsen,Hesham Salah Eldin,Timo E. Strandberg,Jean Ferrières,Rusudan Agladze,Ulrich Laufs,Loukianos S. Rallidis,Laszlo Bajnok,Thorbjorn Gudjonsson,Vincent Maher,Yaakov Henkin,Michele Massimo Gulizia,Aisulu Mussagaliyeva,Gani Bajraktari,Alina Kerimkulova,Gustavs Latkovskis,Omar Hamoui,Rimvydas Šlapikas,Laurent Visser,P. Dingli,Victoria Ivanov,Aneta Boskovic,Mbarek Nazzi,Frank L.J. Visseren,Irena Mitevska,Kjetil Retterstøl,Piotr Jankowski,Ricardo Fontes-Carvalho,Dan Gaita,Marat V. Ezhov,Marina Foscoli,Vojislav Giga,Daniel Pella,Zlatko Fras,Leopoldo Pérez de Isla,Emil Hagström,Roger Lehmann,Leila Abid,Oner Ozdogan,Olena Mitchenko,Riyaz S. Patel +120 more
6.7K
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani,Zobair M. Younossi,Joel E. Lavine,Michael Charlton,Kenneth Cusi,Mary E. Rinella,Stephen A. Harrison,Elizabeth M. Brunt,Arun J. Sanyal +8 more
TL;DR: This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care.
6.3K
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair M. Younossi,Quentin M. Anstee,Milena Marietti,Timothy Hardy,Timothy Hardy,Linda Henry,Mohammed Eslam,Jacob George,Elisabetta Bugianesi +8 more
TL;DR: The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy.
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Alison Halliday,Colin Baigent,François Mach,Borislava Mihaylova,Borislava Mihaylova,Brian A. Ference +5 more
TL;DR: Authors/Task Force Members (François Macha, Colin Baigentb,∗∗,2, Alberico L. Catapanoc), ESC Committee for Practice Guidelines (CPG) (Stephan Windeckeraa), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Patelcl)
4.4K
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
Chun-Tao Wai,Joel K. Greenson,Robert J. Fontana,John D. Kalbfleisch,Jorge A. Marrero,Hari S. Conjeevaram,Anna S.F. Lok +6 more
TL;DR: It is shown that a simple index using readily available laboratory results can identify CHC patients with significant fibrosis and cirrhosis with a high degree of accuracy and may decrease the need for staging liver biopsy specimens among patients with CHC.
4.2K
Related Papers (5)
Mohammed Eslam,Philip N. Newsome,Shiv Kumar Sarin,Quentin M. Anstee,Giovanni Targher,Manuel Romero-Gómez,Shira Zelber-Sagi,Vincent Wai-Sun Wong,Jean-François Dufour,Jörn M. Schattenberg,Takumi Kawaguchi,Marco Arrese,Luca Valenti,Gamal Shiha,Claudio Tiribelli,Hannele Yki-Järvinen,Jian-Gao Fan,Henning Grønbæk,Yusuf Yilmaz,Helena Cortez-Pinto,Claudia P. Oliveira,Pierre Bedossa,Leon A. Adams,Ming-Hua Zheng,Yasser Fouad,Wah-Kheong Chan,Nahum Méndez-Sánchez,Sang Hoon Ahn,Laurent Castera,Elisabetta Bugianesi,Vlad Ratziu,Jacob George +31 more
Mohammed Eslam,Shiv Kumar Sarin,Vincent Wai-Sun Wong,Jian-Gao Fan,Takumi Kawaguchi,Sang Hoon Ahn,Ming-Hua Zheng,Gamal Shiha,Yusuf Yilmaz,Rino Alvani Gani,Shahinul Alam,Yock Young Dan,Jia-Horng Kao,Saeed Hamid,Ian Homer Y. Cua,Wah-Kheong Chan,Diana A. Payawal,Soek Siam Tan,Tawesak Tanwandee,Leon A. Adams,Manoj Kumar,Masao Omata,Jacob George +22 more
[...]